Our data demonstrating broad protection against diverse αSyn-dependent phenotypes by SCD inhibition, along with the established links among αSyn, lipids, and PD, support the continued development of YTX-7739 as a therapeutic agent for synucleinopathies. Here, SCD is linked to synucleinopathy.